Life Technologies last week reported a 1 percent decrease in revenues for its Genetic Analysis unit and flat sales in its Applied Sciences unit in the third quarter, contributing to a 2 percent decline in overall company revenues year over year.

Life Tech also said that its qPCR royalties, which contribute to its Genetic Analysis business, did not decline as much as previously expected in the third quarter due to new licensing programs, but that this effect would likely not linger through the next quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.